|
|
News Breaks | | | | February 6, 2013 | | 06:57 EDT |  | ARNA | Arena Pharmaceuticals coverage resumed with an Outperform at Leerink
Price target range $11-$12. | |
|
News For ARNA From The Last 14 Days Check below for free stories on ARNA the last two weeks. |
|
|
| June 19, 2013 | | 12:22 EDT |  | ARNA | Outlook for obesity drug coverage has improved, says Leerink
Leerink notes that the VA started covering Vivus' (VVUS) Qsymia in April, while a bipartisan group of lawmakers will introduce a bill today to make Medicare begin covering weight-loss drugs. Meanwhile the AMA has labeled obesity a disease for the first time, Leerink added. The firm believes that the community will begin treating obesity as a disease, and it thinks that recent events could enable weight loss drug makers to exceed its estimates. The firm reiterates Outperform ratings on weight loss drug makers Vivus, Arena (ARNA), and Orexigen (OREX). | | | 09:49 EDT |  | ARNA | Weight loss drug makers rise after AMA calls obesity a disease
Makers of anti-obesity drugs are advancing after the American Medical Association designated obesity as a disease. WHAT'S NEW: The AMA recognized obesity as a disease yesterday. Obesity "requires a range of medical interventions," and the treatment and prevention of the condition must be advanced, the organization stated. The AMA's decision will help change the way doctors deal with obesity, AMA board member Patrice Harris, M.D, stated. TODAY'S PRICE ACTION: In early trading, Arena Pharmaceuticals (ARNA) rose 2% to $7.65, while VIVUS (VVUS) climbed 2.4% to $14.10 and Orexigen (OREX) inched up 0.3% to $6.40. | | | 06:52 EDT |  | ARNA | AMA recognizes obesity as disease. NY Times reports
The American Medical Association, or AMA, has officially recognized obesity as a disease, The New York Times reported yesterday. The decision could cause more insurance companies to pay for obesity treatments and spur more doctors to take more steps to combat the condition, the newspaper stated. The AMA overrode a recommendation by a committee that had recommended against making the change, the newspaper noted. Reference Link | | | June 14, 2013 | | 08:11 EDT |  | ARNA | Arena Pharmaceuticals management to meet with Leerink
 Subscribe for More Information | | | June 11, 2013 | | 05:56 EDT | | ARNA | Arena Pharmaceuticals price target raised to $12.50 from $9 at Piper Jaffray
Subscribe for More Information | | | June 7, 2013 | | 09:27 EDT | | ARNA | On The Fly: Pre-market Movers
HIGHER: Concurrent (CCUR), up 9.2% after doubling its dividend... Christopher & Banks (CBK), up 9.1% after quarterly earnings, revenue beat expectations... Gamestop (GME), up 2.5% after Microsoft (MSFT) clarifies how games licensing will works on upcoming Xbox One system... Arena (ARNA), up 1.7% after saying Belviq weight-loss drug available in U.s. next week, triggering milestone payment. LOWER: TiVo (XXX), down 18.7% after announcing patent litigation with Google's (GOOG) Motorola, Cisco (CSCO) and Time Warner Cable (TWC), doubles stock buyback authorization... Iron Mountain (IRM), down 17.2%, Lamar Advertising (LAMR), down 8.3%, Equinix (EQIX), down 7.8%, CBS (CBS), down 2.1%, after IRS forms working group on REIT issues, which could delay some of those companies plans for or consideration of REIT conversion... Intel (INTC), down 0.8% following downgrade to Underweight at Piper Jaffray. | | | 08:17 EDT | | ARNA | Arena says BELVIQ available in U.S. pharmacies within one week
Subscribe for More Information | | | 08:17 EDT | | ARNA | Arena Pharmaceuticals achieves $65M in milestones with Belviq U.S. launch
| | | 08:16 EDT | | ARNA | Arena says BELVIQ available in U.S. pharmacies within one week
Subscribe for More Information | |
|
|
|
|
|
|
